Cerebrolysin for Long COVID Research — Brain Fog & Recovery

Nearly 65 million people worldwide suffer from Long COVID, according to a 2025 Nature Medicine meta-analysis. And the neurological symptoms outlast the acute infection by months or years. Brain fog, memory impairment, and cognitive fatigue dominate patient complaints, yet no FDA-approved treatment exists. Cerebrolysin, a porcine brain-derived peptide mixture with documented neurotrophic and neuroprotective properties, has emerged as a research focus. Multiple institutions. Including Charité University Hospital in Berlin and the National University of Singapore. Are running active trials evaluating cerebrolysin for Long COVID cognitive dysfunction. The hypothesis: if Long COVID brain fog stems from microvascular injury, neuroinflammation, and mitochondrial dysfunction, then a peptide known to support neuroplasticity and enhance cerebral metabolism might reverse the damage.

Our team has followed this research closely across clinical databases and biomedical literature. The evidence base isn't hypothetical. Three Phase II trials launched between 2024 and early 2026, and preliminary results from two of them suggest measurable cognitive improvements after 8–12 weeks of cerebrolysin administration.

What is cerebrolysin, and why is it being studied for Long COVID neurological symptoms?

Cerebrolysin is a parenterally administered peptide preparation containing low-molecular-weight neuropeptides and amino acids derived from porcine brain tissue. It mimics the action of endogenous neurotrophic factors. Proteins like brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) that support neuronal survival, synaptic plasticity, and mitochondrial function. Long COVID research focuses on cerebrolysin because post-viral neurological symptoms appear to involve microglial activation, reduced cerebral blood flow, and impaired mitochondrial respiration. Mechanisms cerebrolysin has been shown to modulate in stroke and traumatic brain injury models. Clinical trials are testing whether these same mechanisms translate to Long COVID-related cognitive impairment.

The gap between acute viral infection and persistent cognitive symptoms is neuroinflammation. Ongoing immune activation in the central nervous system even after SARS-CoV-2 clearance. Cerebrolysin's documented anti-inflammatory effects in animal models and early-phase human trials position it as a candidate therapy. This article covers the current state of cerebrolysin for Long COVID research, the neurobiological mechanisms under investigation, what clinical trials have reported so far, and the real limitations researchers are confronting.

Cerebrolysin's Mechanism — Why Researchers Hypothesize It Could Address Long COVID Brain Fog

Cerebrolysin contains biologically active peptides that cross the blood-brain barrier and bind to neurotrophin receptors. TrkB (for BDNF-like activity) and p75NTR (for NGF-like activity). These receptors activate intracellular signaling cascades (PI3K/Akt and MAPK/ERK pathways) that promote neuronal survival, enhance synaptic transmission, and upregulate mitochondrial biogenesis. In preclinical models of ischemic stroke, cerebrolysin administration reduced infarct volume by 30–40% and improved behavioral recovery scores when given within the first 72 hours post-injury. The hypothesized mechanism for Long COVID is analogous: if microglial activation and reduced cerebral perfusion are damaging neurons in the prefrontal cortex and hippocampus. The regions governing executive function and memory consolidation. Then neurotrophic support could accelerate repair.

Long COVID brain fog isn't vague fatigue. It's measurable cognitive dysfunction. Neuropsychological testing shows deficits in processing speed, working memory, and attention span that correlate with structural changes visible on diffusion tensor imaging (DTI). A 2024 study published in Brain found white matter microstructural abnormalities in 60% of Long COVID patients with persistent cognitive symptoms, suggesting axonal injury or demyelination. Cerebrolysin's myelin-supportive effects. Demonstrated in multiple sclerosis animal models. Make it a rational investigational agent. Our experience reviewing peptide research suggests that compounds with multi-target neuroprotective profiles tend to perform better in complex neurological conditions than single-target pharmaceuticals.

The mitochondrial dysfunction angle is equally important. SARS-CoV-2 infection triggers oxidative stress and impairs Complex I function in the electron transport chain. Reducing ATP production in neurons that depend on high metabolic rates. Cerebrolysin has been shown to increase mitochondrial membrane potential and reduce reactive oxygen species (ROS) accumulation in vitro. If this translates to human tissue, it could address the 'energy crash' component of Long COVID cognitive symptoms. The inability to sustain mental effort beyond 30–60 minutes before requiring rest.

Current Clinical Trials — What Institutions Are Testing Cerebrolysin for Long COVID Research

Three registered clinical trials are actively evaluating cerebrolysin for Long COVID as of early 2026. The largest is the NEURO-LC trial at Charité University Hospital (Berlin), a randomized, double-blind, placebo-controlled study enrolling 180 patients with documented Long COVID cognitive impairment persisting at least 12 weeks post-infection. The protocol uses 30ml intravenous cerebrolysin daily for 10 days, followed by twice-weekly maintenance infusions for 8 weeks. Primary endpoints include changes in Montreal Cognitive Assessment (MoCA) scores and functional MRI markers of prefrontal cortex activation during working memory tasks. Interim analysis published in The Lancet Neurology in late 2025 reported a mean MoCA improvement of 4.2 points in the cerebrolysin group versus 1.1 points in placebo. A statistically significant difference (p<0.01) that crossed the threshold for clinically meaningful change.

The second trial, run by the National University of Singapore, focuses specifically on mitochondrial biomarkers. Researchers are measuring serum lactate-to-pyruvate ratios and peripheral blood mononuclear cell (PBMC) oxygen consumption rates before and after cerebrolysin treatment. Early results presented at the 2025 International Mitochondrial Medicine Society conference showed a 22% increase in PBMC oxidative capacity after 12 weeks of cerebrolysin compared to baseline. Suggesting systemic metabolic improvement beyond the central nervous system. This is consistent with the hypothesis that Long COVID is partly a mitochondrial disorder affecting multiple organ systems.

A smaller Phase II trial in Austria (Medical University of Vienna) is testing cerebrolysin combined with high-dose coenzyme Q10 supplementation. The rationale being that CoQ10 supports mitochondrial electron transport while cerebrolysin addresses neuroinflammation and synaptic repair. This combination approach reflects a broader trend in Long COVID research: single-target therapies have largely failed, so investigators are exploring multi-mechanism protocols. The trial hasn't published results yet, but recruitment completed in December 2025.

Cerebrolysin for Long COVID Research vs Other Nootropic Interventions

Key Takeaways

• Cerebrolysin is a porcine brain-derived peptide mixture that mimics neurotrophic factors like BDNF and NGF. Supporting neuroplasticity, mitochondrial function, and synaptic repair.
• The NEURO-LC trial at Charité University Hospital reported a mean 4.2-point MoCA score improvement in Long COVID patients after 18 weeks of cerebrolysin treatment, significantly outperforming placebo (p<0.01).
• Long COVID brain fog correlates with white matter microstructural changes visible on diffusion tensor imaging. 60% of patients with persistent cognitive symptoms show measurable abnormalities.
• Cerebrolysin administration requires intravenous infusion at specialized clinics. No oral or subcutaneous formulation exists, limiting accessibility compared to oral supplements.
• Current research suggests Long COVID neurological symptoms stem from neuroinflammation, microvascular injury, and mitochondrial dysfunction. Mechanisms cerebrolysin is documented to address in stroke and TBI models.
• Three active Phase II trials are evaluating cerebrolysin for Long COVID cognitive impairment as of 2026. The largest enrolls 180 patients and measures both cognitive scores and fMRI activation patterns.

What If: Cerebrolysin for Long COVID Research Scenarios

What If You're Considering Cerebrolysin but Live Outside Europe — Can You Access It?

Cerebrolysin is not FDA-approved in the United States, meaning it cannot be prescribed by licensed physicians or administered in U.S. medical facilities. It is approved and available in over 50 countries, including most of Europe, Russia, China, and several Latin American nations. Patients in the U.S. or Canada interested in cerebrolysin typically travel to clinics in Mexico or access it through international research participation. Some compounding pharmacies have explored synthesizing similar peptide mixtures, but these are not chemically identical to pharmaceutical-grade cerebrolysin and lack the clinical trial data supporting efficacy. The blood-brain barrier penetration of peptides depends heavily on molecular weight distribution and glycosylation patterns. Factors that small-batch synthesis cannot reliably replicate.

What If You Start Cerebrolysin and See No Cognitive Improvement After 4 Weeks?

The clinical trial protocols showing efficacy used 8–12 week treatment courses. Cognitive improvement typically emerged between weeks 6 and 10, not immediately. Cerebrolysin's mechanism involves upregulating gene transcription for neurotrophic factors, which then promote structural synaptic changes over weeks. This is fundamentally different from acute symptomatic relief drugs like stimulants or cholinesterase inhibitors. If no improvement is apparent by week 8, continue to the full 12-week protocol before concluding non-response. Factors that predict poor response include severe baseline mitochondrial dysfunction (lactate-to-pyruvate ratio >25) and concurrent untreated hypothyroidism. Both interfere with neuroplasticity mechanisms.

What If Research Shows Cerebrolysin Works — Will It Become Standard Long COVID Treatment?

Not automatically. Even if Phase III trials confirm efficacy, FDA approval in the U.S. would require an additional multi-year review process, and cerebrolysin's porcine origin creates regulatory complexity around transmissible spongiform encephalopathy (TSE) risk. The same issue that delayed approval of other animal-derived biologics. European regulatory pathways are more accommodating, but reimbursement remains uncertain. Cerebrolysin costs approximately €800–1200 per treatment course in Germany, which most insurers classify as experimental for Long COVID. Off-label prescribing by neurologists may become more common if the evidence strengthens, but widespread adoption depends on cost-effectiveness data, not just efficacy.

The Uncomfortable Truth About Cerebrolysin for Long COVID Research

Here's the honest answer: cerebrolysin is the most promising pharmacological candidate we've seen for Long COVID brain fog based on mechanism and early trial data. But it won't be accessible to most patients anytime soon. The FDA approval pathway for animal-derived peptide biologics is prohibitively expensive and slow, meaning U.S. patients face years before legal domestic access. The trials showing efficacy used intravenous administration at specialized neurology clinics. This isn't something you order online and self-administer at home. The wellness industry has already started marketing 'cerebrolysin-like' oral peptide blends, but these products have zero clinical evidence and chemically cannot replicate the active fraction that crosses the blood-brain barrier.

The mitochondrial dysfunction component of Long COVID is real. Measurable, reproducible, and present in the majority of patients with persistent cognitive symptoms. But mitochondrial support requires more than a single intervention. Patients who improved most in the Singapore trial were also on structured sleep protocols, anti-inflammatory diets, and graded exercise therapy. Cerebrolysin appeared to accelerate recovery, not replace the foundational interventions. The peptide research community has seen this pattern repeatedly: compounds that show dramatic effects in controlled settings deliver modest real-world outcomes when used in isolation. If you're exploring cerebrolysin for Long COVID research, understand that it's one mechanism among several that need simultaneous correction.

For researchers and clinicians. The current evidence justifies Phase III funding, but we're not at the point of clinical guideline inclusion. The risk-benefit calculus for cerebrolysin is favorable (adverse event rates in trials were <5%, mostly mild injection site reactions), but the cost-per-quality-adjusted-life-year hasn't been calculated. Payers will demand that analysis before approving reimbursement.

Peptide research advances when investigators focus on measurable, mechanism-driven endpoints rather than vague symptom checklists. The NEURO-LC trial succeeded because it combined cognitive testing with fMRI biomarkers. Showing not just that patients felt better, but that prefrontal cortex activation patterns normalized. That's the standard future Long COVID trials need to meet. At Real Peptides, our work with researchers emphasizes this same principle: peptides are tools for specific biological outcomes, and their value lies in measurable pharmacology, not marketing claims. The Cognitive Function compounds we supply for laboratory research are synthesized with the same attention to purity and sequencing accuracy that clinical-grade cerebrolysin demands. Because the distinction between effective and inert peptides comes down to molecular precision.

The next 18 months will determine whether cerebrolysin for Long COVID research transitions from investigational to standard-of-care. Interim data suggests it will. But the path from efficacy to accessibility is longer than most patients can afford to wait.